T. Karikari

Astrocyte reactivity identifies p-tau217-positive individuals at elevated risk of cognitive decline across the Alzheimer’s disease continuum

Plasma phosphorylated tau at threonine 217 (p-tau217) is a robust marker of Alzheimer’s disease (AD) pathology and progression. However, individuals positive for p-tau217 show substantial clinical heterogeneity, suggesting the influence of modifying biological processes. Here, we investigated whether plasma glial...

Association of age with clinical progression across plasma p-tau217 levels

BACKGROUND: Chronological age and plasma p-tau217 each predicts cognitive decline, but whether their prognostic associations interact is unclear. In this study, we examined their joint associations in a memory-clinic cohort. METHODS: We included 3,741 participants from the Pittsburgh ADRC, with up to 28 years of follow...

Proteomic markers linking anxiety phenotypes to Alzheimers disease risk: a multi-analyte proteomic analysis

Altered T1w/T2w-FLAIR Ratio in White Matter Hyperintensities as an Indicator of Structural Integrity Loss: Association with Alzheimer’s Disease and Vascular Dementia

Background: White matter hyperintensities (WMH) are prevalent in dementia, but lesion volume does not capture their microstructural heterogeneity. The T1-weighted to fluid-attenuated inversion recovery (T1w/T2w-FLAIR) ratio is sensitive to myelin, gliosis, and tissue water. We tested whether lesion-specific T1w/T2w-FLA...